glp-1 receptor agonists in idiopathic intracranial hypertension glp 1 Proposed pathophysiological mechanisms underlying IIH and the target The Belly and the Brain:

(2014) Effects of enoxaparin on myeloperoxidase release during hemodialysis

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data

BPC-157 is a synthetic pentadecapeptide associated with gastric-derived cytoprotective systems and is studied for effects on fibroblast activity, endothelial signaling, angiogenesis-related pathways, and nitric oxide-linked signaling

Bacteriostatic water also can't be used for IV administration without an isotonic admixture, because plain bacteriostatic water without a solute is hypotonic and can cause hemolysis on IV push

Youre not fragile